focus -WSS

focus

author：Wikipedia 2025-09-29 19:59:06 - browse：644

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Senate panel passes drug pricing bills, but drops one PBM reform

knowledge

WSS

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Xenotransplantation trials will require adjusting expectations, experts say

Wearables generate powerful data but its not useful to doctors, yet

leisure time

focus

knowledge

Jerome Adams on the need for new antivirals for Covid

Bispecific antibodies are next new thing in cancer immunotherapy

In age of alternative facts, a scholarly course on calling out crap

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Jerome Adams on the need for new antivirals for Covid

Second House panel advances two

Virginia high school admissions case could be legal follow

Inside the rise of 'mukbang' eating videos

Apple is now the first public company to be valued at $3 trillion

It's time to retire 'poor historian' from clinicians' vocabularies

focus

The thinking behind the controversial eating disorder chatbot Tessa

Solving academic medical centers' existential crisis

Altering the blood type of lungs raises potential for universal organs for transplants

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Inside the rise of 'mukbang' eating videos

Bird flu: Don't repeat Covid's 'health versus the economy' framing

knowledge

hotspot

knowledge

knowledge